Determining Follow-Up Approach in Melanoma Based on GEP Risk Level

An expert discusses whether the 31-gene expression profile (GEP) risk classification would change treatment guidelines and how the patient’s GEP risk level would influence the approach to surveillance and follow-up.

Video Player is loading.

Play Video

Play

Mute

Current Time 0:00

/

Duration 3:40

Loaded: 0%

0:00

Stream Type LIVE

Seek to live, currently behind liveLIVE

Remaining Time -3:40

 

1x

Playback Rate

Chapters

• Chapters

Descriptions

• descriptions off, selected

Captions

• captions settings, opens captions settings dialog
• captions off, selected

Audio Track

• en (Main), selected

Fullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

Text

ColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-Transparent

Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparent

Window

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque

Font Size

50%75%100%125%150%175%200%300%400%

Text Edge Style

NoneRaisedDepressedUniformDropshadow

Font Family

Proportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps

Reset restore all settings to the default valuesDone

Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

EP: 1.Limitations and Challenges in Skin Cancer Staging Systems

EP: 2.Utility of Molecular Testing in Skin Cancer Risk Assessment

EP: 3.Gene Expression Profiling and Other Molecular Tests Utilized for Melanoma and Squamous Cell Carcinoma

EP: 4.Utilizing Gene Expression Profiling to Avoid Unnecessary Interventions in a 72-Year-Old Woman With Melanoma

EP: 5.De-Escalating Treatment Plans With Gene Expression Profiling in an 80-Year-Old Man With SCC

EP: 6.Key Takeaways on GEP Testing in Melanoma and SCC

Now Viewing

EP: 7.Determining Follow-Up Approach in Melanoma Based on GEP Risk Level

Video content above is prompted by the following:

• Does the 31-GEP risk classification change your treatment guidelines?
• How would you approach surveillance and follow-up with this patient after knowing their GEP risk level?

Related Videos

Case 2: Poorly Managed GPP Flares and Effisayil 2 Trial Results

Case 1: Experts on a GPP Emergency Case and Effisayil 1 Trial Results

Long-Term Efficacy and Safety of IL-17 Inhibitors in Psoriasis

Determining Appropriate Candidates for JAK Inhibitor Therapy

Enhancing Treatment Adherence: The Impact of Convenience and Topical JAK Inhibitors on Real-World Outcomes

Potential Role of Ruxolitinib Cream in Managing Pediatric Atopic Dermatitis: A Perspective on Use in Ages 2–11

The Need for Nonsteroidal Alternatives in Long-Term Atopic Dermatitis Care: A Focus on Pediatric Patients

Parental Frustrations with Current Treatment Options for Children with Atopic Dermatitis

Navigating Patient Factors When Deciding Treatment for a 38-Year-Old Woman With Severe Atopic Dermatitis

Hepatic Safety of IL-17 Inhibitors in Patients With Psoriasis

Related Content

Advertisement

July 10th 2024

Management of Atopic Dermatitis With Hand and Foot Involvement

Related Content

Video SeriesCase-Based Peer PerspectiveMaximizing Impact and Utility of Prognostic Gene Testing in Melanoma and Squamous Cell Carcinoma

Video Series

|

Case-Based Peer Perspective

|

Maximizing Impact and Utility of Prognostic Gene Testing in Melanoma and Squamous Cell Carcinoma

Advertisement

July 10th 2024

Management of Atopic Dermatitis With Hand and Foot Involvement